Lynne Marie Sullivan is CFO & Head of Corp. Dev. at Unity Biotechnology, Inc. (UBX). They have made 1 open-market trade across 1 company since 2021, most recently 2025-04-02.
CIK 0001727640
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $50K since 2021, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| UBX | SELL · 10b5-1 | 2025-04-02 | 2025-04-03 | $1.03 | $23K | -3.0% | +7.0% | -70.2% |
| UBX | SELL · 10b5-1 | 2025-02-04 | 2025-02-05 | $2.23 | $341 | -12.6% | -27.3% | -60.2% |
| UBX | SELL · 10b5-1 | 2024-11-04 | 2024-11-06 | $1.29 | $175 | +2.6% | +2.6% | +92.2% |
| UBX | SELL · 10b5-1 | 2024-08-02 | 2024-08-06 | $1.53 | $213 | +2.2% | +9.4% | -9.4% |
| UBX | SELL · 10b5-1 | 2024-06-25 | 2024-06-26 | $1.40 | $454 | +4.4% | +7.3% | +5.1% |
| PHGE | BUY | 2021-07-28 | 2021-07-30 | $4.00 | $50K | -18.1% | -21.9% | -53.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.